Dazukibart is a humanized IgG1κ anti-IFNB1 monoclonal antibody of murine origin, being investigated as a potential treatment for dermatomyositis, a complex autoimmune disorder pathologically characterized by the pronounced overexpression of interferon (IFN) inducible genes present within the blood, skin, and muscle tissue of affected patients.